{"product_id":"aemd-vrio-analysis","title":"Aethlon Medical, Inc. (AEMD): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets to Aethlon Medical, Inc. (AEMD)'s sustained success! This VRIO analysis distills the company's competitive foundation down to its essence, revealing precisely how its resources measure up on the critical axes of Value, Rarity, Inimitability, and Organization, leading to the stark conclusion: \u0026amp;O4\u0026amp;. Scroll down now to grasp the full strategic implications of this assessment and see what truly drives Aethlon Medical, Inc. (AEMD)'s market position.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAethlon Medical, Inc. (AEMD) - VRIO Analysis: 1. Proprietary Hemopurifier® Technology Platform (Core Mechanism)\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at a platform technology with strong intellectual property, but its competitive edge hinges entirely on clinical validation proving superiority over existing extracorporeal blood treatments.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math on where Aethlon Medical, Inc. stands with the Hemopurifier® as of late 2025:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eSupporting Data\/Status (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eRemoves enveloped viruses and tumor-derived Extracellular Vesicles (EVs); preclinical data showed \u003cstrong\u003e98.5%\u003c\/strong\u003e removal of platelet-derived EVs in a simulated 4-hour treatment.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eLikely Yes\u003c\/td\u003e\n\u003ctd\u003eUnique mechanism using a plant lectin resin targeting mannose-rich surfaces; holds FDA Breakthrough Device Designation for cancer and viral infections.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eDifficult (High)\u003c\/td\u003e\n\u003ctd\u003eProtected by foundational patents, including US Patent No. 12,409,260 expiring in \u003cstrong\u003e2042\u003c\/strong\u003e (with extension) and European Patent 4136453 expiring in \u003cstrong\u003e2041\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eCompany organized around platform advancement; cash balance was approximately \u003cstrong\u003e$5.8 million\u003c\/strong\u003e as of September 30, 2025, with operating expenses of \u003cstrong\u003e$1.5 million\u003c\/strong\u003e for the quarter ending then.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003eIP protection is strong, but sustained advantage requires successful clinical demonstration of superiority in ongoing trials.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe core value proposition is the selective removal of pathogenic targets using affinity binding. This isn't just filtration; it’s targeted scavenging. The preclinical results showing \u003cstrong\u003e98.5%\u003c\/strong\u003e EV removal in a 4-hour simulation are the strongest evidence of this value.\u003c\/p\u003e\n\u003cp\u003eRarity is supported by the specific mechanism - the plant lectin resin. To be fair, other extracorporeal therapies exist, but none use this exact affinity approach for EVs or certain viruses. The FDA Breakthrough Device Designation underscores the perceived novelty in addressing unmet needs in oncology and infectious disease.\u003c\/p\u003e\n\u003cp\u003eImitability is currently high due to the IP estate. You should note the patent protection extends well into the 2040s, which is a significant moat if the technology proves effective. Still, clinical success is the ultimate barrier to entry that matters most.\u003c\/p\u003e\n\u003cp\u003eOrganizationally, Aethlon Medical, Inc. is focused on execution, evidenced by the recent cost discipline - operating expenses dropped by \u003cstrong\u003e48%\u003c\/strong\u003e year-over-year for the quarter ending September 30, 2025. However, the technology is still investigational. Recruitment for Cohort 2 of the Australian oncology trial was underway as of November 2025, with safety as the primary endpoint. If onboarding takes longer than expected, cash burn becomes a near-term risk.\u003c\/p\u003e\n\u003cp\u003eThe current advantage is temporary because the market waits for proof. The next action item is clear:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eClinical Operations: Deliver safety data from Cohort 2 by Q1 2026.\u003c\/li\u003e\n\u003cli\u003eFinance: Monitor cash runway against the \u003cstrong\u003e$5.8 million\u003c\/strong\u003e balance as of September 30, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAethlon Medical, Inc. (AEMD) - VRIO Analysis: 2. Broad and Extended Patent Portfolio (Intellectual Property)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eProvides market exclusivity for key applications, such as the US patent for Long COVID treatment expiring in \u003cstrong\u003e2042\u003c\/strong\u003e and the European patent for COVID-19-associated coagulopathy expiring in \u003cstrong\u003e2041\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHigh. The recent issuance of patents covering specific, high-profile post-viral conditions is rare for a company at this stage.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLow. Competitors cannot easily replicate the protected uses without licensing or waiting for patent expiration.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHigh. Management is actively securing and announcing these patents, showing a clear strategy to build an IP moat.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSustained. Long-dated patent protection in multiple geographies for novel applications creates a durable barrier.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePatent\/Metric\u003c\/th\u003e\n\u003cth\u003eJurisdiction\u003c\/th\u003e\n\u003cth\u003eKey Application\u003c\/th\u003e\n\u003cth\u003eIssue\/Grant Date\u003c\/th\u003e\n\u003cth\u003eExpiration Year\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS Patent No. 12,409,260\u003c\/td\u003e\n\u003ctd\u003eUS\u003c\/td\u003e\n\u003ctd\u003eLong COVID Treatment\u003c\/td\u003e\n\u003ctd\u003eSeptember 9, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2042\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnitary European Patent 4136453\u003c\/td\u003e\n\u003ctd\u003eEurope (Unitary)\u003c\/td\u003e\n\u003ctd\u003eCOVID-19-associated Coagulopathy (CAC)\u003c\/td\u003e\n\u003ctd\u003eJuly 9, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2041\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOther International Patents\u003c\/td\u003e\n\u003ctd\u003eVarious\u003c\/td\u003e\n\u003ctd\u003eExosome Removal\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eThrough \u003cstrong\u003e2031\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eUS Patent No. 12,409,260 was granted an additional \u003cstrong\u003e385\u003c\/strong\u003e days of patent term due to patent term adjustment.\u003c\/li\u003e\n\u003cli\u003ePreclinical data demonstrated \u003cstrong\u003e98.5%\u003c\/strong\u003e removal of platelet-derived extracellular vesicles (EVs) in a simulated \u003cstrong\u003e4-hour\u003c\/strong\u003e Hemopurifier treatment.\u003c\/li\u003e\n\u003cli\u003eLong COVID is estimated to affect between \u003cstrong\u003e44\u003c\/strong\u003e and \u003cstrong\u003e48 million\u003c\/strong\u003e people in the United States alone.\u003c\/li\u003e\n\u003cli\u003eThe projected economic burden for Long COVID symptoms lasting a year is \u003cstrong\u003e$2 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eOver \u003cstrong\u003e$1 billion\u003c\/strong\u003e has been allocated to Long COVID research funding.\u003c\/li\u003e\n\u003cli\u003eFiscal Q3 2025 (quarter ended Dec 31, 2024): Total operating expenses were \u003cstrong\u003e$1.81M\u003c\/strong\u003e, with a net loss of \u003cstrong\u003e$1.75M\u003c\/strong\u003e ($\u003cstrong\u003e0.13\u003c\/strong\u003e per share).\u003c\/li\u003e\n\u003cli\u003eFiscal Q1 2025 (quarter ended June 30, 2025): Consolidated operating expenses were approximately \u003cstrong\u003e$1.8 million\u003c\/strong\u003e, a decrease of approximately \u003cstrong\u003e31.6%\u003c\/strong\u003e compared to approximately \u003cstrong\u003e$2.6 million\u003c\/strong\u003e for the same period in 2024.\u003c\/li\u003e\n\u003cli\u003eAs of June 30, 2025, Aethlon had a cash balance of approximately \u003cstrong\u003e$3.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe global medical device market is projected to grow to over \u003cstrong\u003e$1 trillion\u003c\/strong\u003e within \u003cstrong\u003e10 years\u003c\/strong\u003e at a \u003cstrong\u003e6%\u003c\/strong\u003e Compound Annual Growth Rate (CAGR).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003cbr\u003e\u003ch2\u003eAethlon Medical, Inc. (AEMD) - VRIO Analysis: 3. FDA Breakthrough Device Designation (Regulatory Status)\n\u003c\/h2\u003e\n\u003cp\u003eThe Aethlon Hemopurifier® has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for two distinct indications. This designation was initially announced for cancer treatment on \u003cstrong\u003eNovember 27, 2018\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe specific indications covered under this designation include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard-of-care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease.\u003c\/li\u003e\n\u003cli\u003eThe treatment of life-threatening viruses that are not addressed with approved therapies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe VRIO assessment for this regulatory status is summarized below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Attribute\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eSupporting Data\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eAccelerates development and review pathways with the US Food and Drug Administration (FDA) for two major areas: unresponsive cancer and life-threatening viruses.\u003c\/td\u003e\n\u003ctd\u003eDesignation granted for indications with significant unmet need.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eThis designation is selective and signals the FDA sees significant potential for improvement over existing standards of care.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eLow\u003c\/td\u003e\n\u003ctd\u003eThis status is granted by the FDA based on pre-clinical\/early clinical data, not something a competitor can simply apply for.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eThe company has successfully navigated the initial steps to secure this status, showing regulatory competence, supported by ongoing investment.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe company's commitment to development is reflected in its financial figures:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eConsolidated operating expenses for the fiscal year ended March 31, 2024, were approximately \u003cstrong\u003e$12.6 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe net loss for the fiscal year ended March 31, 2024, was \u003cstrong\u003e$12.2 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe cash balance as of \u003cstrong\u003eJune 25, 2024\u003c\/strong\u003e, was approximately \u003cstrong\u003e$9.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAs of \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e, there were \u003cstrong\u003e761,318\u003c\/strong\u003e shares of common stock issued and outstanding.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe resulting competitive advantage is assessed as follows:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eCompetitive Advantage\u003c\/th\u003e\n\u003cth\u003eDuration\/Condition\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003eThe advantage lasts as long as the designation is maintained and until a competitor achieves a similar or superior designation for a competing product.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eAethlon Medical, Inc. (AEMD) - VRIO Analysis: 4. Established Australian Oncology Clinical Trial Infrastructure\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides real-world, in-human data on safety and feasibility in a complex patient population (solid tumors unresponsive to anti-PD-1 therapy). The first cohort was completed in mid-2025, with the third patient treated to complete this cohort, leading to DSMB recommendation for advancement.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Having an active, amended trial running in a developed market like Australia is a significant operational asset.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Competitors can set up trials, but replicating the established site relationships and experience gained from the first cohort is harder.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The company successfully completed the first cohort and amended the protocol to include combination therapies like Pembrolizumab, showing adaptive management.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. The advantage is the head start in data collection; it erodes as subsequent cohorts finish and competitors advance their own trials.\u003c\/p\u003e\n\n\u003cp\u003eThe trial is a safety, feasibility, and dose-finding study for the Hemopurifier in patients with solid tumors not responding to anti-PD-1 therapy such as Keytruda or Opdivo. The initial protocol targeted approximately \u003cstrong\u003e9 to 18 patients\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\/Status\u003c\/th\u003e\n\u003cth\u003eContext\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCohort 1 Completion Status\u003c\/td\u003e\n\u003ctd\u003eCompleted (\u003cstrong\u003e3\u003c\/strong\u003e patients treated)\u003c\/td\u003e\n\u003ctd\u003eReported October 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFirst Patient Treatment Date\u003c\/td\u003e\n\u003ctd\u003eJanuary \u003cstrong\u003e29, 2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eRoyal Adelaide Hospital\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSecond Patient Treatment Date\u003c\/td\u003e\n\u003ctd\u003eJune \u003cstrong\u003e2, 2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eRoyal North Shore Hospital\/University of Sydney\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCohort 2 Design\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eTwo\u003c\/strong\u003e Hemopurifier treatments within a one-week period\u003c\/td\u003e\n\u003ctd\u003eRecommended by DSMB\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreclinical EV Removal\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e98.5%\u003c\/strong\u003e removal of platelet-derived EVs\u003c\/td\u003e\n\u003ctd\u003eSimulated \u003cstrong\u003e4-hour\u003c\/strong\u003e treatment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReported EV\/miRNA Decrease (Cohort 1)\u003c\/td\u003e\n\u003ctd\u003eDecreases in large EVs in \u003cstrong\u003e2 of 3\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003ctd\u003eFollowing a single 4-hour HP treatment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReported EV PD-L1 Decrease (Cohort 1)\u003c\/td\u003e\n\u003ctd\u003eDecreases in \u003cstrong\u003eall three\u003c\/strong\u003e participants\u003c\/td\u003e\n\u003ctd\u003eDuring Hemopurifier treatment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReported miRNA Decrease (Cohort 1)\u003c\/td\u003e\n\u003ctd\u003eDecreases in \u003cstrong\u003e7 of 10\u003c\/strong\u003e miRNAs examined in \u003cstrong\u003e2 of 3\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003ctd\u003eFollowing a single 4-hour HP treatment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEV\/miRNA Return to Baseline\u003c\/td\u003e\n\u003ctd\u003eBetween \u003cstrong\u003e1 - 3 weeks\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePost-Hemopurifier treatment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Balance (Latest Reported)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$5.8 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Expenses (3 Months Ended Sep 30, 2025)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$1.5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eDown \u003cstrong\u003e48%\u003c\/strong\u003e from $2.9 million in Q3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAustralian R\u0026amp;D Tax Incentive\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$218,000\u003c\/strong\u003e credit\u003c\/td\u003e\n\u003ctd\u003eContributed to G\u0026amp;A expense reduction in Q2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eKey operational and financial metrics related to the trial execution include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eOperating Expenses Reduction (Q1 2025 vs Q1 2024):\u003c\/strong\u003e \u003cstrong\u003e31.6%\u003c\/strong\u003e reduction, from $2.6 million to $1.8 million.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePatient Population Eligibility:\u003c\/strong\u003e Amended protocol allows patients receiving combination therapy that includes \u003cstrong\u003ePembrolizumab\u003c\/strong\u003e or \u003cstrong\u003eNivolumab\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInitial Safety Outcome:\u003c\/strong\u003e All patients in Cohort 1 were treated without device-related serious adverse events or dose-limiting toxicities.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTrial Sites:\u003c\/strong\u003e Treatments completed at Royal Adelaide Hospital and Royal North Shore Hospital.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAethlon Medical, Inc. (AEMD) - VRIO Analysis: 5. Long COVID\/Infectious Disease Research Pipeline\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Positions the Hemopurifier® to address the massive, ongoing public health need related to post-acute infection syndromes, supported by ongoing collaboration with UCSF. The condition affects an estimated 44 and 48 million people in the United States alone. The projected economic burden for year-long cases is $2 billion.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. While many are researching Long COVID, Aethlon has a specific, patented device application and published preclinical data. Preclinical ex vivo study showed 98.5% removal of platelet-derived EVs in simulated 4-hour treatment.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. The scientific understanding is shared, but the specific device\/resin combination for this application is protected by intellectual property. US Patent No. 12,409,260 for Long COVID treatment is set to issue on September 9, 2025, with an expiration date in 2042.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The collaboration with UCSF and the focus on EV removal in Long COVID show a clear, directed research effort. Findings from the collaboration with the UCSF Long COVID Clinic were presented at the Keystone Symposium in August 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. The advantage is based on being an early mover in applying this specific technology to this specific indication.\u003c\/p\u003e\n\u003cp\u003eKey Statistical and Financial Metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric Category\u003c\/td\u003e\n\u003ctd\u003eSpecific Data Point\u003c\/td\u003e\n\u003ctd\u003eAmount\/Value\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnmet Need Scale (US)\u003c\/td\u003e\n\u003ctd\u003eEstimated Individuals Affected by Long COVID\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e44-48 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnmet Need Scale (Economic)\u003c\/td\u003e\n\u003ctd\u003eProjected Economic Burden for Year-Long Cases\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch Context\u003c\/td\u003e\n\u003ctd\u003eTotal US Research Funding for Long COVID\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e$1 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreclinical Efficacy\u003c\/td\u003e\n\u003ctd\u003ePlatelet-derived EV Removal Rate (Simulated)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e98.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreclinical Context\u003c\/td\u003e\n\u003ctd\u003eSimulated Treatment Duration for Efficacy\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4-hour\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Position\u003c\/td\u003e\n\u003ctd\u003eCash Balance as of March 31, 2025\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$5.5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Position\u003c\/td\u003e\n\u003ctd\u003eCash Balance as of June 30, 2025\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$3.8 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Efficiency\u003c\/td\u003e\n\u003ctd\u003eOperating Expense Reduction (Q1 FY2025 vs Q1 FY2024)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e31.6%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eResearch and Intellectual Property Milestones:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCollaboration with UCSF Long COVID Clinic to evaluate plasma samples.\u003c\/li\u003e\n\u003cli\u003ePreclinical data published in bioRxiv on May 12, 2025.\u003c\/li\u003e\n\u003cli\u003eAbstract accepted for poster presentation at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes (August 2025).\u003c\/li\u003e\n\u003cli\u003eReceived US Patent No. 12,409,260 for Long COVID treatment, issuing September 9, 2025.\u003c\/li\u003e\n\u003cli\u003eReceived Unitary European Patent 4136453 for COVID-19-associated coagulopathy, issued July 9, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAethlon Medical, Inc. (AEMD) - VRIO Analysis: 6. Demonstrated Operational Cost Efficiency (Financial Management)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Extends the cash runway by reducing the burn rate, allowing more capital to be directed toward clinical development rather than overhead.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Low. Many clinical-stage companies cut costs, but the scale here is notable.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: High. Reducing payroll, G\u0026amp;A, and professional fees is a standard, though difficult, management action.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: Management achieved a 48% reduction in operating expenses for the three months ended September 30, 2025, compared to the prior year.\u003c\/p\u003e\n\u003cp\u003eThe operational efficiency is quantified by the following financial metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eThree Months Ended September 30, 2025\u003c\/td\u003e\n\u003ctd\u003eThree Months Ended September 30, 2024\u003c\/td\u003e\n\u003ctd\u003eChange Amount\u003c\/td\u003e\n\u003ctd\u003eChange Percentage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsolidated Operating Expenses\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$1.5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecrease of approximately \u003cstrong\u003e$1.4 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e48%\u003c\/strong\u003e reduction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecrease of \u003cstrong\u003e$1.3 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Balance (as of period end)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$5.8 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe reduction in operating expenses was driven by decreases across specific functional areas:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePayroll and related expenses decreased by approximately \u003cstrong\u003e$778,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe decrease in payroll reflected lower headcount, reduced bonus accruals, and absence of prior-year severance charges.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: None. This is a necessary operational discipline, not a source of sustained competitive advantage against rivals.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAethlon Medical, Inc. (AEMD) - VRIO Analysis: 7. Current Liquidity Position (Cash on Hand)\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eProvides the immediate financial flexibility to fund ongoing operations and clinical trial expenses without immediate reliance on dilutive financing.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eLow. It's a necessary condition for survival, not a unique asset.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eHigh. Cash is fungible; it can be raised through various means.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe company managed its cash to maintain a balance of approximately \u003cstrong\u003e$5.8 million\u003c\/strong\u003e as of September 30, 2025.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAs of September 30, 2025\u003c\/th\u003e\n\u003cth\u003eAs of March 31, 2025\u003c\/th\u003e\n\u003cth\u003ePeriod Ended September 30, 2025 (3 Months)\u003c\/th\u003e\n\u003cth\u003ePeriod Ended September 30, 2024 (3 Months)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5,853,493\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5,501,261\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Current Assets\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6,253,879\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5,949,800\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Current Liabilities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1,404,997\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1,899,286\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsolidated Operating Expenses\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAustralian R\u0026amp;D Tax Incentive Receivable\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$218,314\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eCash and cash equivalents as of September 30, 2025: \u003cstrong\u003e$5,853,493\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents as of March 31, 2025: \u003cstrong\u003e$5,501,261\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eConsolidated operating expenses for the three months ended September 30, 2025: approximately \u003cstrong\u003e$1.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eConsolidated operating expenses for the three months ended September 30, 2024: approximately \u003cstrong\u003e$2.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eDecrease in operating expenses for the three months ended September 30, 2025, compared to 2024: approximately \u003cstrong\u003e48%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAustralian Research and Development Tax Incentive receivable as of September 30, 2025: \u003cstrong\u003e$218,314\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal current liabilities as of September 30, 2025: \u003cstrong\u003e$1,404,997\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eShares issued and outstanding as of September 30, 2025: \u003cstrong\u003e761,318\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eNone. Liquidity is a threshold requirement; it only becomes an advantage if competitors are critically underfunded.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAethlon Medical, Inc. (AEMD) - VRIO Analysis: 8. Exosome\/EV Removal Efficacy Data (Scientific Validation)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides concrete evidence that the device removes circulating factors implicated in disease progression and immunotherapy resistance, such as the \u003cstrong\u003e98.5%\u003c\/strong\u003e removal of platelet-derived EVs in a simulated \u003cstrong\u003e4-hour\u003c\/strong\u003e treatment.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. While EV research is growing, having strong, published ex vivo data tied directly to a device is valuable.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Competitors can develop other EV removal methods, but replicating this specific data set and resin performance is difficult.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The data is being actively published (e.g., bioRxiv submission in \u003cstrong\u003eMay 2025\u003c\/strong\u003e) and presented at key symposia, such as the \u003cstrong\u003eKeystone Symposium\u003c\/strong\u003e on Long COVID and Other Post-Acute Infection Syndromes (\u003cstrong\u003eAugust 10–13, 2025\u003c\/strong\u003e).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Data is a stepping stone; the sustained advantage comes from translating this efficacy into superior clinical outcomes.\u003c\/p\u003e\n\u003cp\u003eThe preclinical ex vivo study demonstrated the following removal efficacy:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eEV Type\/Metric\u003c\/td\u003e\n\u003ctd\u003eRemoval Efficacy\/Observation\u003c\/td\u003e\n\u003ctd\u003eStudy Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatelet-derived EVs (PD-EVs)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e98.5%\u003c\/strong\u003e removal\u003c\/td\u003e\n\u003ctd\u003eSimulated \u003cstrong\u003e4-hour\u003c\/strong\u003e treatment of healthy human plasma\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLarge EVs (Microvesicles)\u003c\/td\u003e\n\u003ctd\u003eDecreases observed\u003c\/td\u003e\n\u003ctd\u003eIn \u003cstrong\u003e2 of 3\u003c\/strong\u003e patients after a single \u003cstrong\u003e4-hour\u003c\/strong\u003e treatment in Australian trial cohort\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEV PD-L1\u003c\/td\u003e\n\u003ctd\u003eDecreased\u003c\/td\u003e\n\u003ctd\u003eIn \u003cstrong\u003eall 3\u003c\/strong\u003e participants after a single \u003cstrong\u003e4-hour\u003c\/strong\u003e treatment in Australian trial cohort\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMicroRNAs (Tested)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e7 of 10\u003c\/strong\u003e decreased\u003c\/td\u003e\n\u003ctd\u003eIn \u003cstrong\u003e2 of 3\u003c\/strong\u003e patients after a single \u003cstrong\u003e4-hour\u003c\/strong\u003e treatment in Australian trial cohort\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEV and MicroRNA Levels (Post-Treatment)\u003c\/td\u003e\n\u003ctd\u003eGenerally returned to baseline within \u003cstrong\u003e1–3 weeks\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eFollowing a single \u003cstrong\u003e4-hour\u003c\/strong\u003e treatment in Australian trial cohort\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eSupporting statistical and financial data points include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe preclinical study showing \u003cstrong\u003e98.5%\u003c\/strong\u003e PD-EV removal was published in \u003cstrong\u003ebioRxiv\u003c\/strong\u003e on \u003cstrong\u003eMay 12, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePreliminary biological changes from the first clinical cohort involved \u003cstrong\u003e3 patients\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAs of \u003cstrong\u003eMarch 31, 2025\u003c\/strong\u003e, Aethlon had a cash balance of approximately \u003cstrong\u003e$5.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFor the three months ended \u003cstrong\u003eJune 30, 2025\u003c\/strong\u003e, consolidated operating expenses were approximately \u003cstrong\u003e$1.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAethlon Medical, Inc. (AEMD) - VRIO Analysis: 9. International Regulatory Approval for Clinical Expansion\n\u003c\/h2\u003e\n\u003cp\u003eAethlon Medical, Inc. received formal approval from India's Central Drugs Standard Control Organization (CDSCO) to initiate a similar oncology trial at Medanta Medicity Hospital.\u003c\/p\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003ePotential access to a second major geographic market for clinical testing and future commercialization in oncology.\u003c\/p\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eReceiving formal approval from India's CDSCO to start a similar oncology study is a key step in globalizing the development path.\u003c\/p\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eRegulatory approvals are jurisdiction-specific and require navigating local requirements.\u003c\/p\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eThe company secured CDSCO approval following Subject Expert Committee clearance and prior Ethics Committee clearance.\u003c\/p\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eThe advantage is temporary; it provided a valuable second site for trials, though the company later decided to discontinue the planned Indian oncology trial to conserve an estimated $500K–$1M and avoid regulatory delays.\u003c\/p\u003e\n\u003cp\u003eThe company reported a cash balance of approximately $5.8 million as of September 30, 2025.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric\u003c\/td\u003e\n\u003ctd\u003ePeriod Ended June 30, 2025\u003c\/td\u003e\n\u003ctd\u003ePeriod Ended September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Balance\u003c\/td\u003e\n\u003ctd\u003eApproximately $3.8 million\u003c\/td\u003e\n\u003ctd\u003eApproximately $5.8 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsolidated Operating Expenses (3 Months)\u003c\/td\u003e\n\u003ctd\u003eApproximately $1.8 million\u003c\/td\u003e\n\u003ctd\u003eDecreased by 48% from prior period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eOperational efficiency metrics related to cost management include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOperating expenses for the three months ended June 30, 2025, were approximately $1.8 million.\u003c\/li\u003e\n\u003cli\u003eThis represented a decrease of approximately $800,000 or approximately 31.6% compared to the same period in 2024.\u003c\/li\u003e\n\u003cli\u003ePayroll and related expenses decreased by approximately $778,000 for the quarter ended September 30, 2025.\u003c\/li\u003e\n\u003cli\u003eGeneral and Administrative expenses declined by approximately $437,000 for the quarter ended September 30, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516105285781,"sku":"aemd-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/aemd-vrio-analysis.png?v=1740142387","url":"https:\/\/dcf-model.com\/es\/products\/aemd-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}